Literature DB >> 16912036

Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity.

Malcolm A Meyn1, Matthew B Wilson, Fadi A Abdi, Nathalie Fahey, Anthony P Schiavone, Jiong Wu, James M Hochrein, John R Engen, Thomas E Smithgall.   

Abstract

Bcr-Abl is the oncogenic protein-tyrosine kinase responsible for chronic myelogenous leukemia. Recently, we observed that inhibition of myeloid Src family kinase activity (e.g. Hck, Lyn, and Fyn) induces growth arrest and apoptosis in Bcr-Abl-transformed cells, suggesting that cell transformation by Bcr-Abl involves Src family kinases (Wilson, M. B., Schreiner, S. J., Choi, H. J., Kamens, J., and Smithgall, T. E. (2002) Oncogene 21, 8075-8088). Here, we report the unexpected observation that Hck, Lyn, and Fyn strongly phosphorylate the SH3-SH2 region of Bcr-Abl. Seven phosphorylation sites were identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry: Tyr89 and Tyr134 in the Abl-derived SH3 domain; Tyr147 in the SH3-SH2 connector; and Tyr158, Tyr191, Tyr204, and Tyr234 in the SH2 domain. SH3 domain Tyr89, the most prominent phosphorylation site in vitro, was strongly phosphorylated in chronic myelogenous leukemia cells in a Src family kinase-dependent manner. Substitution of the SH3-SH2 tyrosine phosphorylation sites with phenylalanine substantially reduced Bcr-Abl-mediated transformation of TF-1 myeloid cells to cytokine independence. The positions of these tyrosines in the crystal structure of the c-Abl core and the transformation defect of the corresponding Bcr-Abl mutants together suggest that phosphorylation of the SH3-SH2 region by Src family kinases impacts Bcr-Abl protein conformation and signaling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16912036     DOI: 10.1074/jbc.M605902200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.

Authors:  Teodora Pene-Dumitrescu; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

2.  DHHC20: a human palmitoyl acyltransferase that causes cellular transformation.

Authors:  Jeremiah M Draper; Charles D Smith
Journal:  Mol Membr Biol       Date:  2010-04       Impact factor: 2.857

Review 3.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

4.  Regulation of myeloproliferation and M2 macrophage programming in mice by Lyn/Hck, SHIP, and Stat5.

Authors:  Wenbin Xiao; Hong Hong; Yuko Kawakami; Clifford A Lowell; Toshiaki Kawakami
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

5.  Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor.

Authors:  Bin Shi; Deeksha Vishwamitra; J Gabrielle Granda; Thomas Whitton; Ping Shi; Hesham M Amin
Journal:  Neoplasia       Date:  2013-06       Impact factor: 5.715

Review 6.  Targeted therapy of chronic myeloid leukemia.

Authors:  Con Sullivan; Cong Peng; Yaoyu Chen; Dongguang Li; Shaoguang Li
Journal:  Biochem Pharmacol       Date:  2010-05-12       Impact factor: 5.858

Review 7.  Hydrogen-deuterium exchange mass spectrometry reveals folding and allostery in protein-protein interactions.

Authors:  Cesar A Ramirez-Sarmiento; Elizabeth A Komives
Journal:  Methods       Date:  2018-04-06       Impact factor: 3.608

8.  Platelet-Derived Growth Factor Receptor α Contributes to Human Hepatic Stellate Cell Proliferation and Migration.

Authors:  Alexander Kikuchi; Tirthadipa Pradhan-Sundd; Sucha Singh; Shanmugam Nagarajan; Nick Loizos; Satdarshan P Monga
Journal:  Am J Pathol       Date:  2017-07-20       Impact factor: 4.307

9.  Enhanced SH3/linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitors.

Authors:  Shoghag Panjarian; Roxana E Iacob; Shugui Chen; Thomas E Wales; John R Engen; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2013-01-09       Impact factor: 5.157

10.  PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.

Authors:  Tasneem Motiwala; Sarmila Majumder; Kalpana Ghoshal; Huban Kutay; Jharna Datta; Satavisha Roy; David M Lucas; Samson T Jacob
Journal:  J Biol Chem       Date:  2008-11-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.